Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ulimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ulimorelin SCHEMBL19586559 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL19958029 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL29375598 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL12197514 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL18813859 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL19958027 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL11983033 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL12197513 | 1.00 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| Ulimorelin SCHEMBL29432592 | 0.98 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14092333 | 0.97 | GHSR (1.00) | GHSRCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2913063-B1 | THERAPEUTIC AGENT FOR USE IN TREATING AMYOTROPHIC LATERAL SCLEROSIS | DAIICHI SANKYO CO LTD (JP) | 2019-09-11 | — | — | EP | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| WO-2017197131-A1 | TREATMENT OF ENTERAL FEEDING INTOLERANCE AND MUSCLE WASTING | LYRIC PHARMACEUTICALS INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197328-A1 | TREATMENT OF ENTERAL FEEDING INTOLERANCE AND MUSCLE WASTING WITH RELAMORELIN | LYRIC PHARMACEUTICALS INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-7452862-B2 | Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists | TRANZYME PHARMA, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-7452862-B2 | Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists | TRANZYME PHARMA, INC. (CA) | 2008-11-18 | — | — | US | disclosed |
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | TRANZYME PHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006009645-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | ATP6V1B2, FABP7, GHSR | GHSR 3/4885CYP3A4 4766/4885CYP2D6 4593/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 2928/4885CYP2D6 2748/4885 |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | GHSR 47/4885CYP3A4 4837/4885CYP2D6 4829/4885 |
| US-20080051383-A1 | METHODS OF USING MACROCYCLIC AGONISTS OF THE GHRELIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS | GHSR, GIPR, GHRHR | GHSR 1/4885CYP3A4 1192/4885CYP2D6 719/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885CYP3A4 4608/4885CYP2D6 4373/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | GHSR 1/4885CYP3A4 2981/4885CYP2D6 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.